Brokerages forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report sales of $94.00 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Neurocrine Biosciences’ earnings. The firm is scheduled to announce its next quarterly earnings results on Tuesday, February 13th.
On average, analysts expect that Neurocrine Biosciences will report full year sales of $94.00 million for the current fiscal year. For the next fiscal year, analysts forecast that the business will post sales of $372.34 million per share, with estimates ranging from $220.00 million to $511.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the prior year, the firm posted ($0.43) earnings per share.
Shares of Neurocrine Biosciences (NBIX) opened at $80.68 on Monday. Neurocrine Biosciences has a 52 week low of $38.43 and a 52 week high of $83.84. The stock has a market capitalization of $7,139.61, a PE ratio of -36.34, a P/E/G ratio of 75.47 and a beta of 0.35. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
In other news, insider Kyle Gano sold 24,818 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the completion of the transaction, the insider now owns 84,596 shares of the company’s stock, valued at $6,010,545.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin Charles Gorman sold 3,750 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $78.89, for a total value of $295,837.50. The disclosure for this sale can be found here. Insiders have sold 121,780 shares of company stock valued at $9,012,926 in the last three months. 4.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. GW&K Investment Management LLC grew its holdings in shares of Neurocrine Biosciences by 12.0% during the fourth quarter. GW&K Investment Management LLC now owns 91,529 shares of the company’s stock worth $7,102,000 after purchasing an additional 9,785 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $496,000. Frontier Capital Management Co. LLC purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $9,328,000. Schwab Charles Investment Management Inc. grew its holdings in shares of Neurocrine Biosciences by 6.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 409,522 shares of the company’s stock worth $31,775,000 after purchasing an additional 25,834 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of Neurocrine Biosciences by 457.9% during the fourth quarter. Bank of Montreal Can now owns 10,767 shares of the company’s stock worth $835,000 after purchasing an additional 8,837 shares in the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.